Jiangsu Nhwa In-licenses China Rights to Anti-Psychotic from Zysis

Jiangsu Nhwa Pharma acquired China rights to an extended-release form of aripiprazole (Ablify), an anti-psychotic drug being developed by Zysis of the UK. Ablify was indicated to treat schizophrenia, bipolar and major depressive disorder. Developed by Japan's Otsuka, its US patent expired in 2014. Zysis' product is a once-weekly oral formulation of the drug. Nhwa paid $500,000 upfront and will pay another $200,000 once Zysis transfers technology. Nhwa will also pay a non-disclosed royalty on sales. More details.... Stock Symbol: (SHZ: 2262) Share this with colleagues: // //